Post navigation

The Centers for
Medicare & Medicaid Services (CMS) has opened a National Coverage
Determination (NCD) process for adding hepatitis C testing to Medicare.

As you know, the U.S. Preventive Services Task Force (USPSTF) recently
updated its recommendations and gave a “B” grade to testing at risk
populations and a one-time test for everyone born between 1945 and 1965.
Under the Affordable Care Act, Medicare can cover preventive services
with a USPSTF grade of “A” or “B” and the services must be at no cost to
the Medicare beneficiary.

As a result, CMS is officially reviewing the
data and arguments for covering hepatitis C testing through its NCD
process.

CMS has opened a 30 day public comment period to collect input from
advocates, medical providers, public health officials, and other
stakeholders. This is a great opportunity to encourage CMS to act
quickly and make sure that hepatitis C testing is available for those in
the Medicare program, or entering the program, who are at risk or are
in the birth cohort. You can read more about the NCD process and how to
submit public comment here

NVHR will sent an Alert soon with more information and talking points to help craft your comments.

The study is aimed at assessing the safety and immunogenicity of HCV prime-boost vaccinations ChAd3-hliNSmut and MVA-hliNSmut, administered intramuscularly in healthy volunteers and DAA treated patients. To read the entire study, click here Share This PageFollow Us … Continue reading → The post The study is aimed at assessing the safety and immunogenicity of HCV […]

The purpose of this study is to evaluate the efficacy and tolerability of DAA-based regimens in the clinical practice in HIV/HCV-coinfected patients. Hypothesis: The efficacy and tolerability of all DAA-based regimens in the clinical practice is different to what is … Continue reading → The post Real-life Security and Efficacy of DAA-based Therapy in 1,000 […]